SecBot SecBot
SECBOTREPLAY Home › Report › GILD

GILD · Gilead Sciences is holding its 2026 Annual Meeting, where shareholders…

GILEAD SCIENCES, INC. · DEFA14A filed Mar 20, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Mar 20, 2026 at 16:01 ET

Gilead Sciences is holding its 2026 Annual Meeting, where shareholders will vote on several key proposals. The board recommends voting in favor of re-electing all nine director nominees, ratifying Ernst & Young as auditors, approving executive compensation, and amending the equity incentive plan. The board opposes three shareholder proposals requesting an independent board chair, a report on patent exclusivity impacts on patient access, and a report on ESG/DEI compensation metrics.

  • Annual shareholder meeting scheduled for April 30, 2026
  • Nine director nominees up for re-election, including Daniel P. O'Day and Kelly A. Kramer
  • Board recommends ratification of Ernst & Young as independent auditors
  • Board recommends approval of amended 2022 Equity Incentive Plan

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access